[Rockville, Maryland, Mar 11, 2019] — HighTide Therapeutics, today announced that it has been invited to deliver two presentation at Phar-East 2019, to be held March 18–20 in Singapore.
Date: Tuesday, March 19, 2019
Jeffrey Dao, Operating and Business Development Officer
Date: Wednesday, March 20, 2019
“East Meets West, the Quest for Cure, Global Development of HTD1801 for Treating Primary Sclerosing Cholangitis”
Dr. Liping Liu, Founder, CEO & CSO
“We are pleased that HighTide has been selected to present at Phar-East 2019. This is an exciting year for HighTide and Phar-East 2019 is an ideal venue for us to introduce HighTide and its pipeline of innovative therapies for patients suffering from non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and acute pancreatitis, diseases that lack approved therapies,” said Liping Liu, Founder, CEO and CSO of HighTide Therapeutics.
About HighTide Therapeutics
HighTide Therapeutics Inc., founded in Shenzhen China in 2011, is dedicated to the discovery and development of innovative therapeutics for people suffering from chronic liver diseases, gastrointestinal diseases and metabolic disorders with large and unsatisfied market needs. The company has global operations in China, USA and Australia.